
Nanobiotix SA licences NBTXR3 to J&J
NBTXR3 is currently being evaluated across different solid tumour indications including NANORAY‑312, a global Phase III pivotal study in ...

Dutch NLC has €20m in first close of new Health Impact Fund
According to NLC, there's a huge funding gap that prevents patents from becoming successful companies, with 95% of all healthtech inventions never...

Mithra raises €20m through private placement
Under the terms of the Private Placement, Armistice Capital committed to subscribe for 10 million new shares atz a share price of 2€ per share , of...

Oxford Biomedica expands agreement with Cabaletta Bio
Philadelphia-based clinical-stage biotech Cabaletta Bio focuses on developing and launching the first curative targeted cell therapies for patients...

Novo Nordisk takes over Inversago Pharma Inc.
As competiion for Novo Nordisk A/S’ subcutanously administered blockbuster GLP1-receptor blocker semaglutide is growing, particularly as an obesity...

Promising viral gene therapy for genetic kidney disease
UK resesearchers have engineered an adeno-associated virus vector to treat the heriditary steroid-resistant nephrotic syndrome in children, which is...

New detection method for protein degraders
The research team from MPI of Biochemistry and the University of Waterloo have developed a new way to detect those CRLs in the fleet that are...